Global Locations

Lopinavir



Chemical Properties of 'Lopinavir'

CAT No. :

CS-O-30497
CAS Registry No. : 192725-17-0
Category : API Standards
Molecular Weight: 628.8
Molecular Formula : C₃₇H₄₈N₄O₅



OTHER INFORMATION of 'Lopinavir'
Purity : Not less than 95 %
Therapeutic : Antiretroviral / Anti-HIV
Purity : Not less than 95 %
Therapeutic : Antiretroviral / Anti-HIV
IUPAC Name :(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
Applicationnotes :NULL
Synonym :Not Available
References :NULL
Smileys :CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
Appearance :White to off white solid
Color / Form :Colorless solid from ethyl acetone
Melting Point :124-127 °C
Solubility :Practically insoluble
Use Classification :Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Hazard Class :Skin Irrit. 2 (90.16%)
EC Number :844-598-9
UNII :2494G1JF75
NCI Thesaurus Code :C2095
RXCUI :195088
MeSH Entry Terms :A 157378.0
Other Synonyms :Lopinavir
Removed Synonyms :Kaletra
Vapor Pressure : 3.4X10-24 mm Hg at 25 °C (est)
Label Ingredient : LOPINAVIR
NDC Code :0074-0522-60, 0074-1575-21, 0074-2605-21, 0074-3956-46, 0074-6799-22, 0074-6799-30, 0527-1947-48, 11819-342-20, 21695-362-12, 31722-556-12, 31722-556-31, 31722-556-32, 31722-556-60, 31722-603-12, 31722-603-60, 53808-0276-1, 54868-5566-0, 55289-947-12, 65015-299-49, 65015-299-50, 66336-624-12, 68071-2348-2, 68258-1972-1, 70518-0091-0, 70518-0091-1, 70518-0091-2
Disposal Methods :SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Toxicity Summary :As lopinavir is only available in combination with ritonavir, experience with acute lopinavir overdose in isolation is limited. The risk related to overdose appears more pronounced in pediatric patients. One case report detailed a fatal cardiogenic shock in a 2.1kg infant following an approximately 10-fold overdose of Kaletra oral solution, while other reported reactions to overdose in infants include complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure. The oral Kaletra solution is highly concentrated, posing a greater risk of overdose, and contains approximately 42% (v/v) ethanol, further increasing risk in children and infants. There is no antidote for lopinavir overdose. Treatment of overdose should consist largely of supportive measures and close observation of vital signs and clinical status of the affected patient. Consideration should be given to the removal of unabsorbed drug using gastric lavage or activated charcoal, if clinically indicated. Dialysis is unlikely to be of benefit as lopinavir is highly protein-bound, but may help to remove ethanol and propylene glycol from the circulation in the case of overdose with Kaletra oral solution.
Hepatotoxicity :Some degree of serum aminotransferase elevations occur in a high proportion of patients taking lopinavir containing antiretroviral regimens. Moderate-to-severe elevations in serum aminotransferase levels (>5 times the upper limit of normal) are found in 3% to 10% of patients, although rates may be higher in patients with HIV-HCV coinfection. These elevations are usually asymptomatic and self-limited and can resolve even with continuation of the medication. Clinically apparent liver disease due to lopinavir/ritonavir occurs, but is rare. The latency to onset of symptoms or jaundice is usually 1 to 8 weeks and the pattern of serum enzyme elevations varies from hepatocellular to cholestatic or mixed. The injury is usually self-limited; however, fatal cases have been reported. In addition, initiation of lopinavir/ritonavir based highly active antiretroviral therapy can lead to exacerbation of an underlying chronic hepatitis B or C in coinfected individuals, typically arising 2 to 12 months after starting therapy, and associated with a hepatocellular pattern of serum enzyme elevations and increases in serum levels of hepatitis B virus (HBV) DNA or hepatitis C virus (HCV) RNA. Lopinavir therapy has not been clearly linked to lactic acidosis and acute fatty liver that is reported in association with several nucleoside analogue reverse transcriptase inhibitors.
Interactions :Possible pharmacokinetic interaction with amiodarone, bepridil (no longer commercially available in the US), lidocaine (systemic), and quinidine (increased plasma concentrations of the antiarrhythmic agent). Use with caution. Monitor plasma concentrations of the antiarrhythmic agents if used concomitantly with lopinavir/ritonavir.
Antidoteand Emergency Treatment :/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
Human Toxicity Excerpts :/CASE REPORTS/ A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. The patient (normal renal and liver functions) was diagnosed with a Burkitt lymphoma for which he was treated with cyclophosphamide day 1 to 5; doxorubicin day 1; methotrexate day 10; and vincristine day 1 and 8. At day 12, he suffered from abdominal pain associated with constipation. Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated. /The researchers/ speculate that an interaction between ritonavir/lopinavir and vincristine was responsible for this severe toxicity. Vincristine is transported by P-gp and is metabolized via CYP3A5. Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction.
Non Human Toxicity Excerpts :/LABORATORY ANIMALS: Acute Exposure/ Lethal oral dose of lopinavir when given alone was greater than 2500 mg/kg. The acute NOEL ranged from 39/20 mg/kg for rats to 20/10 mg/kg for mice given the 2:1 oral combination. The combination of the two substances showed a low acute toxic potential. Clinical signs of toxicity included reduced activity, ataxia, dyspnea, salivation, and discoloration urine.
Protein Binding :Lopinavir is >98% protein-bound in plasma. It binds to both alpha-1-acid glycoprotein and albumin, but exhibits a greater affinity for alpha-1-acid glycoprotein.
Exact Mass :628.36247064
InChI :InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
InchIKey :KJHKTHWMRKYKJE-SUGCFTRWSA-N
Canonical SMILES :CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
Isomeric SMILES :CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
Product Description :Lopinavir is a dicarboxylic acid diamide that is amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha- to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class, it is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir. It has a role as an antiviral drug, a HIV protease inhibitor and an anticoronaviral agent. It is a member of amphetamines and a dicarboxylic acid diamide.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Lopinavir


Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir).

It was patented in 1995 and approved for medical use in 2000.





This page contains information about Lopinavir , Lopinavir cas, Lopinavir synthesis, Lopinavir suppliers

What is Lopinavir ?
Lopinavir falls under API Standards of Lopinavir.NULL
What is the CAS Number of Lopinavir?
The CAS Number of Lopinavir is 192725-17-0
Who are the suppliers of Lopinavir?
CLEARSYNTH is a worldwide supplier of Lopinavir

List of Lopinavir API Standards

Related compounds of Lopinavir

Looking for a discounted price or need more info for 'Lopinavir (CS-O-30497)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Lopinavir (CS-O-30497)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.